New pill may prevent chemotherapy delays in breast cancer patients

NCT ID NCT05394285

Completed Disease control Sponsor: Henan Cancer Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a drug called hetrombopag in 60 advanced breast cancer patients whose platelets dropped too low from chemotherapy. The goal was to see if the drug could safely raise platelet counts and prevent treatment delays or dose reductions. Patients took the pill daily when platelets were low, and doctors monitored their response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: hetrombopag olamine tablets
What this could lead to: If it works, this could help advanced breast cancer patients avoid treatment delays or dose reductions due to low platelets, making chemotherapy safer and more effective.
What could go wrong: This is a small, early-phase study with only 60 participants, so results may not apply to all patients. The drug may cause side effects or not work as expected.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Henan Cancer Hospital

Zhengzhou, Henan, China
Henan Cancer Hospital

Zhengzhou, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.